The failure rate for those already entered Phase 1 trials to be successfully approval, is around 90%, also it usually takes 10 to 15 years to final FDA approval stage.
Reata, took 21 years to successfully develop Skyclarys to obtain FDA APPROVAL.
Coincidentally, NEU’s DAYBUE, also is taken 21 years from the scratch to FDA APPROVAL.
To develop a drug, is a marathon exercise with very low success rate, imo.
- Forums
- ASX - By Stock
- NEU Vs Reata
NEU
neuren pharmaceuticals limited
Add to My Watchlist
6.14%
!
$13.31

The failure rate for those already entered Phase 1 trials to be...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.31 |
Change
0.770(6.14%) |
Mkt cap ! $1.655B |
Open | High | Low | Value | Volume |
$12.96 | $14.00 | $12.91 | $19.76M | 1.453M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3000 | $13.30 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.33 | 3716 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3000 | 13.300 |
2 | 10200 | 13.200 |
1 | 2500 | 13.190 |
2 | 1750 | 13.180 |
1 | 50 | 13.170 |
Price($) | Vol. | No. |
---|---|---|
13.330 | 3716 | 1 |
13.370 | 3716 | 1 |
13.390 | 600 | 1 |
13.400 | 3783 | 2 |
13.430 | 3716 | 1 |
Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online